Canopus Biopharma Incorporated Stock Shares Owned By Institutions
| CBIA Stock | USD 0.0001 0.00 0.00% |
Canopus BioPharma Incorporated fundamentals help investors to digest information that contributes to Canopus BioPharma's financial success or failures. It also enables traders to predict the movement of Canopus Pink Sheet. The fundamental analysis module provides a way to measure Canopus BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Canopus BioPharma pink sheet.
Canopus |
Canopus BioPharma Incorporated Company Shares Owned By Institutions Analysis
Canopus BioPharma's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Canopus BioPharma Incorporated are shares owned by institutions. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Canopus Fundamentals
| Shares Outstanding | 9.3 M | |||
| Net Income | 1.68 M | |||
| Cash Flow From Operations | 1.98 M | |||
| Beta | -2.23 | |||
| Market Capitalization | 364.56 K | |||
| Total Asset | 1.56 M | |||
| Retained Earnings | (10.29 M) | |||
| Current Asset | 92 K | |||
| Current Liabilities | 2.36 M | |||
| Z Score | -8.4 | |||
| Net Asset | 1.56 M |
About Canopus BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canopus BioPharma Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canopus BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canopus BioPharma Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Canopus Pink Sheet
Canopus BioPharma financial ratios help investors to determine whether Canopus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canopus with respect to the benefits of owning Canopus BioPharma security.